Vivos Therapeutics, Inc. (NASDAQ: VVOS)

Sector: Healthcare Industry: Medical Devices CIK: 0001716166
Market Cap 15.27 Mn
P/B 6.03
P/E -0.89
P/S 0.88
ROIC (Qtr) -104.65
Div Yield % 0.00
Rev 1y % (Qtr) 75.73
Total Debt (Qtr) 12.50 Mn
Debt/Equity (Qtr) 4.94
Add ratio to table...

About

Vivos Therapeutics, Inc., a company commonly recognized by its stock symbol VVOS, operates in the medical technology industry. The company is dedicated to the development and commercialization of innovative diagnostic and multi-disciplinary treatment modalities for patients with dentofacial abnormalities and related medical conditions, such as obstructive sleep apnea (OSA) and snoring in adults. Vivos Therapeutics primarily focuses on expanding awareness of and providing treatment options for OSA through the dental industry, which it identifies...

Read more

Investment thesis

Bull case

  • Healthy cash reserves of 3.09M provide 2.74x coverage of short-term debt 1.13M, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong free cash flow of (15.37M) provides 2.99x coverage of acquisition spending (5.13M), indicating disciplined M&A strategy.
  • Operating cash flow of (14.39M) exceeds working capital of (1.65M) by 8.72x, showing strong operational efficiency.
  • Tangible assets of 15.02M provide robust 2.02x coverage of current liabilities 7.44M, showing strong asset backing.
  • Cash position of 3.09M fully covers payables of 2.10M by 1.47x, showing strong vendor relationship management.

Bear case

  • Cash reserves of 3.09M provide limited coverage of acquisition spending of (5.13M), which is -0.60x, suggesting aggressive expansion might strain liquidity if market conditions deteriorate.
  • The company's operating cash flow of (14.39M) shows concerning coverage of stock compensation expenses of 671000, with a -21.45 ratio indicating potential earnings quality issues.
  • Free cash flow of (15.37M) provides weak coverage of capital expenditures of 975000, with a -15.76 ratio suggesting additional external financing needs for growth initiatives.
  • Operating earnings of (17.10M) show weak coverage of depreciation charges of 1.01M, with a -16.92 ratio indicating high capital intensity and potential reinvestment needs.
  • Operating cash flow of (14.39M) barely covers operating expenses of 1.01M with a -14.23 ratio, suggesting thin operational efficiency margins and limited flexibility.

Peer comparison

Companies in the Medical Devices
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ABT Abbott Laboratories 173.80 Bn 32.73 5.47 12.94 Bn
2 SYK Stryker Corp 141.15 Bn 43.48 5.62 15.86 Bn
3 MDT Medtronic plc 123.47 Bn 25.92 3.55 29.10 Bn
4 BSX Boston Scientific Corp 112.80 Bn 38.92 5.62 11.44 Bn
5 EW Edwards Lifesciences Corp 45.66 Bn 33.38 7.76 0.70 Bn
6 DXCM Dexcom Inc 27.52 Bn 32.91 5.90 1.34 Bn
7 STE STERIS plc 24.13 Bn 34.08 4.14 2.05 Bn
8 PODD Insulet Corp 17.33 Bn 70.38 6.87 1.01 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 0.88 2.13
EV to Cash from Ops. EV/CFO -1.56 2.75
EV to Debt EV to Debt 1.80 17.25
EV to EBIT EV/EBIT -1.31 2.89
EV to EBITDA EV/EBITDA -1.47 4.53
EV to Free Cash Flow [EV/FCF] EV/FCF -1.46 29.36
EV to Market Cap EV to Market Cap 1.47 25.09
EV to Revenue EV/Rev 1.30 32.80
Price to Book Value [P/B] P/B 6.03 4.73
Price to Earnings [P/E] P/E -0.89 -2.04
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Div Coverage (Qtr) 0.00 40.22
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 1.59
Dividend per Basic Share Div per Share (Qtr) 0.00 0.10
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.37
Interest Coverage Int. cover (Qtr) 0.00 196.93
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) -71.65 -152.08
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) -51.09 8,476.58
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 -0.44
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -36.09 -792.16
EBITDA Growth (1y) % EBITDA 1y % (Qtr) -28.53 3.79
EBIT Growth (1y) % EBIT 1y % (Qtr) -36.09 -301.80
EBT Growth (1y) % EBT 1y % (Qtr) -36.09 -121.44
EPS Growth (1y) % EPS 1y % (Qtr) 68.84 -87.51
FCF Growth (1y) % FCF 1y % (Qtr) -17.59 10.43
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 7.12 38.21
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.68 0.55
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.02
Cash Ratio Cash Ratio (Qtr) 0.42 1.80
Current Ratio Curr Ratio (Qtr) 0.78 4.18
Debt to Equity Ratio Debt/Equity (Qtr) 4.94 1.20
Interest Cover Ratio Int Coverage (Qtr) 0.00 196.93
Times Interest Earned Times Interest Earned (Qtr) 0.00 196.93
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) -92.90 -2,396.63
EBIT Margin % EBIT Margin % (Qtr) -98.77 -2,478.60
EBT Margin % EBT Margin % (Qtr) -98.77 -2,690.42
Gross Margin % Gross Margin % (Qtr) 55.70 30.80
Net Profit Margin % Net Margin % (Qtr) -98.80 -2,821.53